Review of LDL-C Lowering with Focus on New and Emerging Agents

J Fam Pract. 2020 Sep;69(7 Suppl):S69-S74.

Abstract

Identify the benefits and limitations of statin therapy as a treatment option for lowering LDL-C. Intensify treatment in appropriate patients or refer for intensification. Describe the safety and efficacy of ezetimibe, bempedoic acid, PCSK9 inhibitors, LDL apheresis. Describe the safety and efficacy of medications in late-stage development or under review by the FDA for LDL-C reduction.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cholesterol, LDL / drug effects*
  • Dicarboxylic Acids / therapeutic use
  • Education, Medical, Continuing
  • Fatty Acids / therapeutic use
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Hypercholesterolemia / drug therapy
  • PCSK9 Inhibitors
  • Proprotein Convertase 9 / therapeutic use
  • Review Literature as Topic

Substances

  • Cholesterol, LDL
  • Dicarboxylic Acids
  • Fatty Acids
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • PCSK9 Inhibitors
  • 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid
  • Proprotein Convertase 9